Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B.

Humans Hepatitis B, Chronic / drug therapy Hepatitis B Surface Antigens / blood Male Female Adult Retrospective Studies Hepatitis B Antibodies / blood Antiviral Agents / therapeutic use Middle Aged Hepatitis B e Antigens / blood Interferon-alpha / therapeutic use Hepatitis B virus / immunology Hepatitis B Core Antigens / immunology Treatment Outcome Drug Therapy, Combination Seroconversion Young Adult Polyethylene Glycols / therapeutic use Recombinant Proteins / therapeutic use
Hepatitis B surface antigen antiviral functional cure level of anti-HBc antibody pegylated interferon

Journal

Virulence
ISSN: 2150-5608
Titre abrégé: Virulence
Pays: United States
ID NLM: 101531386

Informations de publication

Date de publication:
Dec 2024
Historique:
medline: 25 9 2024
pubmed: 25 9 2024
entrez: 24 9 2024
Statut: ppublish

Résumé

Predicting hepatitis B surface antigen (HBsAg) clearance is important for chronic hepatitis B (CHB) patients receiving pegylated interferon-alfa (Peg-IFN) therapy. We aimed to determine the predictive value of serum hepatitis B core antibody (anti-HBc) for HBsAg clearance. A total of 189 HBeAg-negative CHB patients who received Peg-IFN based therapy were retrospectively included and classified into two groups: nucleos(t)ide analogues (NAs) add-on Peg-IFN group (add-on group,

Identifiants

DOI: 10.1080/21505594.2024.2404965 PMID: 39317345
pubmed: 39317345
doi: 10.1080/21505594.2024.2404965
doi:

Substances chimiques

Hepatitis B Surface Antigens 0
Hepatitis B Antibodies 0
Antiviral Agents 0
Hepatitis B e Antigens 0
Interferon-alpha 0
Hepatitis B Core Antigens 0
Polyethylene Glycols 3WJQ0SDW1A
Recombinant Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2404965

Auteurs

Jian Wang (J)

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.

Zhiyi Zhang (Z)

Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Li Zhu (L)

Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, China.

Qing Zhang (Q)

Department of Infectious Diseases, Huai'an No. 4 People's Hospital, Huai'an, Jiangsu, China.

Shaoqiu Zhang (S)

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.

Yifan Pan (Y)

Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.

Jiacheng Liu (J)

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.

Fei Cao (F)

Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Tao Fan (T)

Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Ye Xiong (Y)

Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Shengxia Yin (S)

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.

Xiaomin Yan (X)

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.

Yuxin Chen (Y)

Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.

Chuanwu Zhu (C)

Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, China.

Jie Li (J)

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.

Xingxiang Liu (X)

Department of Clinical Laboratory, Huai'an No. 4 People's Hospital, Huai'an, Jiangsu, China.

Chao Wu (C)

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
ORCID: 0000-0002-1657-010X

Rui Huang (R)

Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
ORCID: 0000-0002-3189-7960

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Association of hepatitis B core antibody level...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Hépatite chronique › Hépatite B chronique › Association of hepatitis B core antibody level...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes d'hépatite virale › Antigènes de l'hépatite virale B › Antigènes de surface du virus de l'hépatite B › Association of hepatitis B core antibody level...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Association of hepatitis B core antibody level...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Association of hepatitis B core antibody level...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Anticorps de l'hépatite › Anticorps de l'hépatite B › Association of hepatitis B core antibody level...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Association of hepatitis B core antibody level...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Association of hepatitis B core antibody level...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes d'hépatite virale › Antigènes de l'hépatite virale B › Antigènes e du virus de l'hépatite virale B › Association of hepatitis B core antibody level...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Interféron alpha › Association of hepatitis B core antibody level...
questionsmedicales.fr › Virus › Virus de l'hépatite › Hepadnaviridae › Orthohepadnavirus › Virus de l'hépatite B › Association of hepatitis B core antibody level...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes viraux › Antigènes d'hépatite virale › Antigènes de l'hépatite virale B › Antigènes de la nucléocapside du virus de l'hépatite virale B › Association of hepatitis B core antibody level...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Association of hepatitis B core antibody level...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Association of hepatitis B core antibody level...
questionsmedicales.fr › Phénomènes du système immunitaire › Séroconversion › Association of hepatitis B core antibody level...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Association of hepatitis B core antibody level...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomédicaux et dentaires › Polymères › Polyéthylène glycols › Association of hepatitis B core antibody level...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines recombinantes › Association of hepatitis B core antibody level...